Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free MLTX Stock Alerts

MoonLake Immunotherapeutics (MLTX) Competitors

MoonLake Immunotherapeutics logo
$17.01 -0.55 (-3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$16.96 -0.05 (-0.29%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MLTX vs. DNTH, INDV, LEGN, CRNX, and NNNN

Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Dianthus Therapeutics (DNTH), Indivior (INDV), Legend Biotech (LEGN), Crinetics Pharmaceuticals (CRNX), and Anbio Biotechnology (NNNN). These companies are all part of the "pharmaceutical products" industry.

How does MoonLake Immunotherapeutics compare to Dianthus Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

MoonLake Immunotherapeutics presently has a consensus target price of $23.08, suggesting a potential upside of 35.67%. Dianthus Therapeutics has a consensus target price of $115.55, suggesting a potential upside of 28.04%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
3 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.38
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,973.33%. Dianthus Therapeutics' return on equity of -38.85% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -66.56% -50.23%
Dianthus Therapeutics -7,973.33%-38.85%-36.42%

In the previous week, Dianthus Therapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 4 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.73 beat Dianthus Therapeutics' score of 0.63 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dianthus Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dianthus Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.52N/A
Dianthus Therapeutics$2.04M2,408.61-$162.34M-$4.10N/A

Summary

Dianthus Therapeutics beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Indivior?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

MoonLake Immunotherapeutics presently has a consensus target price of $23.08, suggesting a potential upside of 35.67%. Indivior has a consensus target price of $39.33, suggesting a potential downside of 0.65%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
3 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.38
Indivior
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to MoonLake Immunotherapeutics' net margin of 0.00%. MoonLake Immunotherapeutics' return on equity of -66.56% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -66.56% -50.23%
Indivior 19.44%-219.26%29.40%

In the previous week, Indivior had 16 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 20 mentions for Indivior and 4 mentions for MoonLake Immunotherapeutics. Indivior's average media sentiment score of 0.81 beat MoonLake Immunotherapeutics' score of 0.73 indicating that Indivior is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Indivior
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Indivior has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.52N/A
Indivior$1.24B3.90$210M$1.9520.30

Summary

Indivior beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Legend Biotech?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Legend Biotech had 4 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.73 beat Legend Biotech's score of 0.22 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -28.86%. Legend Biotech's return on equity of -21.93% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -66.56% -50.23%
Legend Biotech -28.86%-21.93%-13.21%

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.52N/A
Legend Biotech$1.03B5.13-$296.80M-$0.80N/A

MoonLake Immunotherapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

MoonLake Immunotherapeutics presently has a consensus target price of $23.08, suggesting a potential upside of 35.67%. Legend Biotech has a consensus target price of $58.31, suggesting a potential upside of 104.52%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
3 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.38
Legend Biotech
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Legend Biotech beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Crinetics Pharmaceuticals?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 4 mentions for MoonLake Immunotherapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat MoonLake Immunotherapeutics' score of 0.73 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Crinetics Pharmaceuticals
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Crinetics Pharmaceuticals' return on equity of -41.46% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -66.56% -50.23%
Crinetics Pharmaceuticals -6,046.22%-41.46%-37.43%

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.52N/A
Crinetics Pharmaceuticals$7.70M558.01-$465.32M-$4.94N/A

MoonLake Immunotherapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

MoonLake Immunotherapeutics presently has a consensus target price of $23.08, suggesting a potential upside of 35.67%. Crinetics Pharmaceuticals has a consensus target price of $76.75, suggesting a potential upside of 88.34%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
3 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.38
Crinetics Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Crinetics Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Anbio Biotechnology?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 0.75 beat MoonLake Immunotherapeutics' score of 0.73 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MoonLake Immunotherapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Anbio Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MoonLake Immunotherapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the S&P 500.

Anbio Biotechnology's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -66.56% -50.23%
Anbio Biotechnology N/A N/A N/A

Anbio Biotechnology has higher revenue and earnings than MoonLake Immunotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.52N/A
Anbio Biotechnology$8.65M485.73$6.40MN/AN/A

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics currently has a consensus target price of $23.08, suggesting a potential upside of 35.67%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
3 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.38
Anbio Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

MoonLake Immunotherapeutics and Anbio Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLTX vs. The Competition

Export
MetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.26B$3.39B$6.24B$11.86B
Dividend YieldN/A2.20%2.73%5.21%
P/E RatioN/A38.8529.0428.48
Price / SalesN/A157.28477.1060.43
Price / CashN/A57.8827.6236.52
Price / Book3.987.039.676.67
Net Income-$227.32M$23.62M$3.55B$332.64M
7 Day Performance2.10%3.67%1.70%2.01%
1 Month Performance-2.02%7.17%5.62%9.19%
1 Year Performance-59.40%67.04%34.42%39.59%

MoonLake Immunotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
3.2128 of 5 stars		$17.01
-3.1%		$23.08
+35.7%		N/A$1.26BN/AN/A2
DNTH
Dianthus Therapeutics
3.3289 of 5 stars		$85.58
-1.8%		$115.55
+35.0%		N/A$4.67B$2.04MN/A80
INDV
Indivior
2.766 of 5 stars		$34.59
+0.8%		$39.33
+13.7%		N/A$4.22B$1.24B21.091,051
LEGN
Legend Biotech
3.3378 of 5 stars		$22.53
-4.7%		$58.31
+158.8%		N/A$4.17B$1.03BN/A2,965
CRNX
Crinetics Pharmaceuticals
3.3475 of 5 stars		$38.31
-0.8%		$76.75
+100.3%		N/A$4.03B$7.70MN/A210

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel